Establishing physical activity in breast cancer: self-report versus activity tracker

Wagoner, Chad W.; Choi, Seul Ki; Deal, Allison M.; Lee, Jordan T.; Wood, William A.; Muss, Hyman B.; Nyrop, Kirsten A.

doi:10.1007/s10549-019-05263-3

Cited by 20 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Physical activity levels before, during, and after cancer treatment have been established as robust predictors of clinical outcomes as well as quality of life 12 , 13 . Compared with self-report assessments of physical activity, wearable devices offer more objective and fine-grained activity data 14 . Research generally supports the validity of commercial wearable devices for activity measurement 15 , although there is some evidence that step counts may be less accurate with slower gait speed or assistive device use 16 .…”

Section: Consumer Wearable Devices In Oncology Researchmentioning

confidence: 99%

Harnessing consumer smartphone and wearable sensors for clinical cancer research

Low

2020

npj Digit. Med.

View full text Add to dashboard Cite

As smartphones and consumer wearable devices become more ubiquitous, there is a growing opportunity to capture rich mobile sensor data continuously, passively, and in real-world settings with minimal burden. In the context of cancer, changes in these passively sensed digital biomarkers may reflect meaningful variation in functional status, symptom burden, quality of life, and risk for adverse clinical outcomes. These data could enable real-time remote monitoring of patients between clinical encounters and more proactive, comprehensive, and personalized care. Over the past few years, small studies across a variety of cancer populations support the feasibility and potential clinical value of mobile sensors in oncology. Barriers to implementing mobile sensing in clinical oncology care include the challenges of managing and making sense of continuous sensor data, patient engagement issues, difficulty integrating sensor data into existing electronic health systems and clinical workflows, and ethical and privacy concerns. Multidisciplinary collaboration is needed to develop mobile sensing frameworks that overcome these barriers and that can be implemented at large-scale for remote monitoring of deteriorating health during or after cancer treatment or for promotion and tailoring of lifestyle or symptom management interventions. Leveraging digital technology has the potential to enrich scientific understanding of how cancer and its treatment affect patient lives, to use this understanding to offer more timely and personalized support to patients, and to improve clinical oncology outcomes.

show abstract

Section: Consumer Wearable Devices In Oncology Researchmentioning

confidence: 99%

Harnessing consumer smartphone and wearable sensors for clinical cancer research

Low

2020

npj Digit. Med.

View full text Add to dashboard Cite

show abstract

“…Accelerometer counted steps had large interindividual differences with no systematic influence from time since start or type of treatment, while self-reported PA first declined, then rebounded and was lower under chemotherapy. Correlation between device-based and subjective assessments was "strong" and thereby higher than in other studies on breast cancer [36,47]. Agreement about adherence to both activity recommendations classified as "fair": a narrow majority of self-reports conformed to device data ratings.…”

Section: Discussionmentioning

confidence: 64%

“…Discrepancies concerning walking time resulted from higher estimates in self-reports. This may be caused by the device's low resolution of 15 min-segments, but also by patients overreporting PA time [35,36]. For step recommendation adherence, higher self-report-and device-based ratings were equally common.…”

Section: Discussionmentioning

confidence: 99%

“…PA questionnaires are also common with cancer patients [3,4,6,12,13,[29][30][31][32][33]. Combination with activity trackers show patients seem more inclined towards overestimation [34][35][36] than underestimation [37]. Importantly, while in some studies results were independent of the mode of PA assessment [37,38], others found differences for one but not for the other: In a study by Goedendorp et al [39], groups differed in their self-reported PA but not when compared via Actometer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer

Helbrich

Braun

Hanusch

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose This study examines congruence between self-reported and device-measured physical activity data in women with early breast cancer and compares trajectories under different treatments. Methods Women with non-metastatic breast cancer were recruited before primary therapy. In four weeks distributed over six months after treatment start, patients reported time spent on work, transport, chores and sports via diary and wore Garmin® vivofit 3 accelerometers to assess steps taken. Associations between these measures and agreement regarding guideline adherence were tested with Spearman’s Correlation Coefficient and Weighted Kappa statistic. Effects of time and treatment were evaluated using mixed analyses of variance. Results Ninety-nine participants (median age = 50) were treated with adjuvant (N= 23), neoadjuvant (N= 21) or without chemotherapy (N= 55). Coherence between self-report and device data was strong (r = 0.566). Agreement about reaching recommendations was only “fair” (kappa coefficient = 0.321 and 0.249, resp.). Neither treatment or week nor their interaction had effects on step counts (all p > 0.05). Self-reported activity time was lower for patients with chemotherapy than for those without (adjuvant: ∆ = 69min, p= 0.006, neoadjuvant: ∆ = 45min, p= 0.038) and lower in week 18 than in week 3 (∆ = 43min, p= 0.010). Conclusion Results show that consumer-grade activity monitors and self-reports correlate but show different perspectives on physical activity in breast cancer patients. In general, patients perceive some decline regardless of primary treatment regimen. Those affected should be offered assistance to gain the benefits of activity. Accelerometers may help professionals to identify these individuals and patients to verify appraisal of their activity levels.

show abstract

“…It is important for trainers, patients, and researchers to implement current technologies, including activity trackers, accelerometers, or wearables to obtain objective measurements of PA complementary to subjective and personal perceptions [137,138]. Monitoring all the possible variables may help in the establishment of more effective exercise programs.…”

Section: Specific Considerations Of Training Women With Bcmentioning

confidence: 99%

Physical Activity as an Imperative Support in Breast Cancer Management

Ortega

Fraile-Martínez

García-Montero

et al. 2020

Cancers

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy and the second cause of cancer-related death among women. It is estimated that 9 in 10 cases of BC are due to non-genetic factors, and approximately 25% to 30% of total breast cancer cases should be preventable only by lifestyle interventions. In this context, physical activity represents an excellent and accessible approach not only for the prevention, but also for being a potential support in the management of breast cancer. The present review will collect the current knowledge of physical activity in the background of breast cancer, exploring its systemic and molecular effects, considering important variables in the training of these women and the evidence regarding the benefits of exercise on breast cancer survival and prognosis. We will also summarize the various effects of physical activity as a co-adjuvant therapy in women receiving different treatments to deal with its adverse effects. Finally, we will reveal the impact of physical activity in the enhancement of quality of life of these patients, to conclude the central role that exercise must occupy in breast cancer management, in an adequate context of a healthy lifestyle.

show abstract

Establishing physical activity in breast cancer: self-report versus activity tracker

Cited by 20 publications

References 26 publications

Harnessing consumer smartphone and wearable sensors for clinical cancer research

Harnessing consumer smartphone and wearable sensors for clinical cancer research

Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer

Physical Activity as an Imperative Support in Breast Cancer Management

Contact Info

Product

Resources

About